In a regulatory 8-K filing, the company states: "Allogene Therapeutics, Inc. informs its investors that it does not hold cash deposits or securities at Silicon Valley Bank."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALLO:
- Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
- Allogene Therapeutics price target lowered to $20 from $29 at Truist
- Allogene Therapeutics announces publication of case review in Molecular Therapy
- Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy
- Allogene Therapeutics price target lowered to $15 from $18 at B. Riley
